1. Home
  2. CMMB vs ETS Comparison

CMMB vs ETS Comparison

Compare CMMB & ETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMMB
  • ETS
  • Stock Information
  • Founded
  • CMMB 2004
  • ETS 2020
  • Country
  • CMMB Israel
  • ETS United States
  • Employees
  • CMMB N/A
  • ETS N/A
  • Industry
  • CMMB Biotechnology: Pharmaceutical Preparations
  • ETS Trucking Freight/Courier Services
  • Sector
  • CMMB Health Care
  • ETS Industrials
  • Exchange
  • CMMB Nasdaq
  • ETS Nasdaq
  • Market Cap
  • CMMB 13.7M
  • ETS 14.7M
  • IPO Year
  • CMMB N/A
  • ETS 2025
  • Fundamental
  • Price
  • CMMB $3.28
  • ETS $0.79
  • Analyst Decision
  • CMMB Strong Buy
  • ETS
  • Analyst Count
  • CMMB 2
  • ETS 0
  • Target Price
  • CMMB $26.50
  • ETS N/A
  • AVG Volume (30 Days)
  • CMMB 260.4K
  • ETS 193.0K
  • Earning Date
  • CMMB 11-13-2025
  • ETS 10-14-2025
  • Dividend Yield
  • CMMB N/A
  • ETS N/A
  • EPS Growth
  • CMMB N/A
  • ETS N/A
  • EPS
  • CMMB N/A
  • ETS N/A
  • Revenue
  • CMMB N/A
  • ETS $2,585,885.00
  • Revenue This Year
  • CMMB N/A
  • ETS N/A
  • Revenue Next Year
  • CMMB N/A
  • ETS N/A
  • P/E Ratio
  • CMMB N/A
  • ETS N/A
  • Revenue Growth
  • CMMB N/A
  • ETS 6.59
  • 52 Week Low
  • CMMB $2.39
  • ETS $0.75
  • 52 Week High
  • CMMB $9.84
  • ETS $4.23
  • Technical
  • Relative Strength Index (RSI)
  • CMMB 59.76
  • ETS N/A
  • Support Level
  • CMMB $3.03
  • ETS N/A
  • Resistance Level
  • CMMB $3.50
  • ETS N/A
  • Average True Range (ATR)
  • CMMB 0.21
  • ETS 0.00
  • MACD
  • CMMB 0.02
  • ETS 0.00
  • Stochastic Oscillator
  • CMMB 64.21
  • ETS 0.00

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

About ETS Elite Express Holding Inc. Class A Common Stock

Elite Express Holding Inc is a holding company that operates through its wholly owned subsidiary and specializes in last-mile delivery services within California. Its core business focuses on retrieving packages from distribution hubs and ensuring their prompt and secure delivery to recipients' doorsteps. Committed to innovation and efficiency, its mission is to optimize last-mile logistics by providing efficient, reliable, and innovative delivery solutions. The company mainly competes in the route delivery industry, which has several material barriers of entry, including: Substantial time and capital investment, Technological proficiency, Regulatory barriers, Balancing service quality and cost efficiency, and Effective Management.

Share on Social Networks: